Cosentyx sensoready 150 MG penml
Ended Awarded Last action
- Contract number
- SPE2DR26F8E5U
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,139
Award facts
- Contract value 100% obligated
- $10,139.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,139.39 to AmerisourceBergen Drug Corp for Cosentyx Sensoready 150 mg pen/ml, a pharmaceutical product used in the treatment of autoimmune conditions. This contract represents a firm fixed-price delivery order with no set-aside designation, awarded on January 16, 2026, with an ultimate completion date of January 20, 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc. (doing business as Amerisourcebergen), a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in the federal medical supply chain. The parent company holds a larger indefinite delivery contract with DLA Troop Support Medical valued at $999,999,999.00 through December 31, 2031. AmerisourceBergen's portfolio of federal contracts demonstrates extensive capability in fulfilling diverse pharmaceutical procurement requirements for military treatment facilities, veterans' healthcare programs, and other federal medical institutions across multiple therapeutic domains including oncology, diabetes management, pain management, and specialized medical treatments.
Quick answers
Who was awarded contract SPE2DR26F8E5U?
SPE2DR26F8E5U was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26F8E5U worth?
The government has obligated $10,139 on SPE2DR26F8E5U.
Is contract SPE2DR26F8E5U an order under another contract?
Yes. SPE2DR26F8E5U is a delivery order under SPE2DR25D3202, an indefinite delivery contract.
Was contract SPE2DR26F8E5U competed?
The extent of competition for SPE2DR26F8E5U was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award